Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial
Standard
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial. / Salwender, Hans; Elmaagacli, Ahmet; Merz, Maximilian; Miah, Kaya; Benner, Axel; Haenel, Mathias; Jehn, Christian; Mai, Elias K; Bertsch, Uta; Blau, Igor W; Scheid, Christof; Hose, Dirk; Seckinger, Anja; Jauch, Anna; Raab, Marc S; Luntz, Steffen P; Besemer, Britta; Munder, Markus; Brossart, Peter; Fuhrmann, Stephan; Lindemann, Hans-Walter; Weisel, Katja; Duerig, Jan; Goldschmidt, Hartmut.
in: LEUKEMIA, Jahrgang 35, Nr. 10, 10.2021, S. 3007-3011.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Andere (Vorworte u.ä.) › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial
AU - Salwender, Hans
AU - Elmaagacli, Ahmet
AU - Merz, Maximilian
AU - Miah, Kaya
AU - Benner, Axel
AU - Haenel, Mathias
AU - Jehn, Christian
AU - Mai, Elias K
AU - Bertsch, Uta
AU - Blau, Igor W
AU - Scheid, Christof
AU - Hose, Dirk
AU - Seckinger, Anja
AU - Jauch, Anna
AU - Raab, Marc S
AU - Luntz, Steffen P
AU - Besemer, Britta
AU - Munder, Markus
AU - Brossart, Peter
AU - Fuhrmann, Stephan
AU - Lindemann, Hans-Walter
AU - Weisel, Katja
AU - Duerig, Jan
AU - Goldschmidt, Hartmut
PY - 2021/10
Y1 - 2021/10
U2 - 10.1038/s41375-021-01298-y
DO - 10.1038/s41375-021-01298-y
M3 - Other (editorial matter etc.)
C2 - 34031532
VL - 35
SP - 3007
EP - 3011
JO - LEUKEMIA
JF - LEUKEMIA
SN - 0887-6924
IS - 10
ER -